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The calcium-activated potassium 
channel KCa3.1 is an important 
modulator of hepatic injury
Linda Sevelsted Møller1,2, Annette Dam Fialla1, Robert Schierwagen3, Matteo Biagini4, 
Christian Liedtke5, Wim Laleman6, Sabine Klein3, Winfried Reul3, Lars Koch Hansen7, 
Maj Rabjerg4, Vikrant Singh8, Joaquin Surra9, Jesus Osada10, Roland Reinehr11, 
Ove B. Schaffalitzky de Muckadell1, Ralf Köhler12,* & Jonel Trebicka1,3,*
The calcium-activated potassium channel KCa3.1 controls different cellular processes such as 
proliferation and volume homeostasis. We investigated the role of KCa3.1 in experimental and 
human liver fibrosis. KCa3.1 gene expression was investigated in healthy and injured human and 
rodent liver. Effect of genetic depletion and pharmacological inhibition of KCa3.1 was evaluated in 
mice during carbon tetrachloride induced hepatic fibrogenesis. Transcription, protein expression and 
localisation of KCa3.1 was analysed by reverse transcription polymerase chain reaction, Western blot 
and immunohistochemistry. Hemodynamic effects of KCa3.1 inhibition were investigated in bile duct-
ligated and carbon tetrachloride intoxicated rats. In vitro experiments were performed in rat hepatic 
stellate cells and hepatocytes. KCa3.1 expression was increased in rodent and human liver fibrosis and 
was predominantly observed in the hepatocytes. Inhibition of KCa3.1 aggravated liver fibrosis during 
carbon tetrachloride challenge but did not change hemodynamic parameters in portal hypertensive 
rats. In vitro, KCa3.1 inhibition leads to increased hepatocyte apoptosis and DNA damage, whereas 
proliferation of hepatic stellate cells was stimulated by KCa3.1 inhibition. Our data identifies KCa3.1 
channels as important modulators in hepatocellular homeostasis. In contrast to previous studies in vitro 
and other tissues this channel appears to be anti-fibrotic and protective during liver injury.
Hepatic fibrosis is the common response to any form of chronic liver injury and upon progression it undermines 
liver function and initiates portal hypertension. Activated and myofibroblast-like hepatic stellate cells (HSC), 
instigated and perpetuated by inflammation secondary to hepatocellular damage, are considered the main cel-
lular source for the extracellular matrix during liver fibrogenesis1. Nevertheless, quiescent HSC were reported to 
contribute to progenitor cells and liver regeneration2. Hepatocytes show a high regenerative potential upon injury 
and frequently react with adaption of the cell volume, which is suggested to be controlled by the calcium-activated 
potassium channel KCa3.13. This channel is activated by Ca2+ binding to constitutively bound calmodulin, and 
the K+-efflux and concomitant water efflux leads to cell volume reduction. In hepatoma cell-lines KCa3.1 acti-
vation seems to be crucial for volume restoration after cell swelling caused by hypotonic stress and thereby for 
hepatocyte volume control3.
Besides its role in cell volume regulation, the KCa3.1 channel modulates other cellular processes such as 
cell proliferation and endothelium-dependent vasorelaxation4–8, and was shown to be pathomechanistically 
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implicated in renal and pulmonary fibrosis9–12. Indeed, KCa3.1 deficiency in mice blunted renal fibrosis13, and 
the KCa3.1 inhibitor TRAM-34 was shown to suppress fibrogenic properties of myofibroblasts in vitro14. Yet, 
the pathomechanistic roles of KCa3.1 in liver fibrosis especially in experimental studies and in human situation 
remains unclear, especially in regards to the potential effect of the channel on the high hepatic regenerative poten-
tial compared to other parenchymal organs.
Phenotypically, KCa3.1 deficient mice are characterized by a sizable splenomegaly, which is linked to KCa3.1’s 
well-established effect on erythrocyte volume regulation15. Furthermore, the mice have a mild arterial hyperten-
sion16, are hyperactive and have higher bodyweights than wild type littermates17.
In this study, we hypothesized pathomechanistic roles of KCa3.1 in liver injury and fibrosis and tested whether 
genetic deficiency or pharmacological blockade alters fibrotic remodelling and expression of profibrotic media-
tors in experimental rodent models.
Materials and Methods
Human liver specimen. Liver biopsies were performed using the Menghini method (17G Menghini 
needle, Hepafix, Braun, Germany). Biopsies were collected from 54 patients at the Department of Medical 
Gastroenterology, Odense University Hospital. We included patients, who for clinical reasons were scheduled to 
undergo liver biopsy, and used the excess tissue for further analyses. Oral and written informed consent was given 
prior to biopsy, and all experiments were performed in accordance with the approved guidelines and regulations. 
The study was approved by The Regional Scientific Ethical Committees for Southern Denmark (case number 
S-20110115) and was in agreement with the 1975 Declaration of Helsinki.
Samples were immediately stored in 4% formalin and sent to routine histological staining and evaluation. 
METAVIR score was evaluated blinded by a hepatopathologist and performed on all biopsies. Patients were classi-
fied into groups based on fibrosis score; non-fibrotic (n = 12), F1–F2 fibrosis (n = 20) and F3–F4 fibrosis (n = 22) 
(Table 1).
Animal studies. All animals within this study received human care according to the criteria outlined in the 
Guide for the Care and Use of Laboratory Animals. Animals were housed in a room with controlled temperature 
and humidity in a 12-hour light cycle. KCa3−/− mice, also known as Kcnn4 deficient mice, were obtained from 
own breeding colonies5. The genetic background for the KCa3.1 deficient mice is C57BLJ/6 × 129 Ola. KCa3.1 
knockout mice were bred by homozygote breeding and KCa3.1 deficiency was furthermore verified by quantita-
tive polymerase chain reaction (qPCR). We used KCa3.1+/+ or KCa3.1+/− animals as wt controls. Experimental 
protocols were approved by the Danish Animal Experience Inspectorate (2012-15.2934-00264).
For rat studies we used Sprague-Dawley rats. The responsible committee for animal studies in North 
Rhine-Westphalia approved this part of the study (LANUV 8.87-50.10.31.08.28).
Mouse models of fibrosis. We used KCa3.1−/− mice and corresponding wt littermates at age 12–16 weeks. The 
mice were challenged with carbon tetrachloride (CCl4) (1 ml/kg i.p.) twice weekly. Animals were grouped accord-
ing to a CCl4 exposure time of 8 weeks to induce fibrosis18 and 12 weeks to induce advanced fibrosis or cirrhosis19. 
For each exposure group we included 8–10 wt and 8–10 KCa3.1 knockout mice. Age and sex matched untreated 
wt and KCa3.1−/− mice (n = 10 wt, 10 KCa3.1−/−) served as controls.
Rat models of fibrosis. For CCl4 intoxication in rats we exposed rats (n = 4) with an initial body weight of 
100–120 g to CCl4 inhalation 1 l/min for 14–16 week as described previously20,21. For thioacetamide (TAA) 
induced injury we administered TTA in 200–250 g rats (n = 4) in their drinking water for 18 weeks as previously 
described22.
Bile duct ligation (BDL) and transection was performed under anaesthesia with ketamine/xylazine as previ-
ously described20,21. Hemodynamic experiments were conducted four weeks after BDL surgery in 3 rats.
Treatment with the KCa3.1-blocker Senicapoc. For pharmacological studies, wt mice were used. 
Animals were exposed to CCl4 for 12 weeks, and allocated to receive either normal chow (placebo) (n = 10) or 
the oral KCa3.1 antagonist Senicapoc (n = 10). Senicapoc (ICA-17043) was synthesized as previously described23 
and animals received a dosage of 30 mg/kg/day mixed in the chow. Senicapoc was administered in the fodder and 
initiated 48 hours prior to the first CCl4 injection. Food intake was measured weekly until termination. Prior to 
termination, animals were anaesthetised with fentanyl/fluanisone and midazolam, blood was collected through 
penetration of the retro-orbital sinus, and plasma was separated by centrifuge and stored at − 80 degrees Celsius 
until analysed. The concentration of Senicapoc was measured by mass spectrometry (TSQ Quantum Access 
MAX, ThermoFisher Scientific, Waltham, MA, USA).
Hemodynamic studies. In vivo measurements of portal pressure (PP), mean arterial pressure (MAP) and 
heart rate (HR) were performed in BDL (n = 3) and CCl4 exposed (n = 3) rats during anaesthesia with ketaminen/
xylazine (78 and 12.5 mg/kg i.m. respectively) as previously described20,21,24,25. Briefly, following midline laparot-
omy, a PE-50 catheter was inserted into the ileocecal vein and progressed to the portal vein. This was followed 
by insertion of a similar catheter in the femoral artery for MAP measurement. Both catheters were connected to 
a pressure transducer (Hugo Sachs Electronic, March-Hugstetten, Germany). Hemodynamic stabilization was 
awaited before proceeding and subsequently 100 nM of the KCa3.1 antagonist TRAM-34 was injected as bolus. 
Continuous monitoring of HR, MAP and PP was performed for the following 20 minutes.
Quantitative RT-PCR. For murine samples RNA was isolated using TRIZOL reagent (Invitrogen, 
United Kingdom) and DNAse digestion using RNase free DNase 1 (Thermo Scientific, CA, USA) according 
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to manufactures instructions. cDNA was synthesized with iScript cDNA Synthesis Kit (Bio-Rad, CA, USA). 
qRT-PCR was performed using SYBR Green Supermix (Bio-Rad, CA, USA) on the Stratagene MX3000 qPCR 
instrument (Agilent Technologies, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as 
endogenous control.
For gene expression analyses in rat and cell studies, RNA isolation, reverse transcription and detection by 
RT-PCR were performed by TaqMan method as described previously20,21,26. 18S rRNA served as endogenous 
control.
Results are expressed as 2−ΔΔCt, and express the x-fold increase of gene expression compared to the control 
group, and in murine studies results were compared to untreated wt.
Western blotting. Western blot was performed on samples from untreated and fibrotic wt and KCa3.1−/− 
mice (12 weeks CCl4 exposure) for Proliferating Cell Nuclear Antigen (PCNA; Santa Cruz-Biotechnology, Santa 
Cruz, USA). Proto-oncogene tyrosine-protein kinase Src (c-Src) activity was analysed by phosphorylation either 
at Thr418 or at Thr530 (both Santa Cruz-Biotechnology, Santa Cruz, USA). Activation of c-Jun N-terminal 
kinases 1 and 2 (pJNK1&2; Life technologies, Darmstadt, Germany) and total JNK (Santa Cruz-Biotechnology, 
Santa Cruz, USA) was assessed by their phosphorylation at Thr183, respectively Tyr185. GAPDH served as 
endogenous control.
Snap frozen liver samples were processed as previously described using sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE)20,21,26. Ponceau S staining was used to confirm equal protein loading. 
Membranes were blocked and incubated with respective antibodies. Thereafter, membranes were incubated with 
the corresponding secondary peroxidase-coupled antibodies (Santa Cruz-Biotechnology, Santa Cruz, USA).
After enhanced chemiluminescence (ECL; Amersham, Bucks, UK), digital detection was evaluated using 
Chemi-Smart (PeqLab Biotechnologies, Erlangen, Germany). Data are expressed as means ± standard error of 
the mean (SEM) with values of controls normalized to 100%.
Hepatic hydroxyproline content. Analogue segments (200 mg) of snap-frozen murine livers were hydro-
lysed in HCl (6 N). Hepatic hydroxyproline content was determined photometrically in liver hydrolysates as 
previously described26,27.
Isolation of primary rat HSC and hepatocytes. Primary rat HSCs were isolated as described previ-
ously21,26. In brief, primary HSC were isolated in a two-step pronase-collagenase perfusion from the livers of 
healthy rats (n = 5) and fractionated by density gradient centrifugation. Viability and purity were controlled and 
were systematically over 95%. Cells were seeded on uncoated plastic culture dishes. Experiments were performed 
1 day after isolation to investigate effects in quiescent HSCs and 7 days after isolation or after the first passage 
(10 days) when HSCs were fully activated. Primary hepatocytes were isolated from male rats (n = 5) as described 
previously28.
Furthermore, these cells were incubated with the KCa3.1 inhibitor TRAM-34 and activator SKA-31 for 
24 hours respectively, and mRNA expression for collagen1, α -SMA and TGFβ were measured. To evaluate effects 
on cell cycle progression, mRNA expression of cyclin E1 (indicating S-phase initiation) and cyclin A2 (S-phase 
progression) was measured in 3 different isolations of hepatocytes and HSC incubated with TRAM-34 and 
SKA-31.
To evaluate effect of KCa3.1 inhibition and activation on cell volume, rat hepatocytes and HSC were incubated 
with TRAM-34 and SKA-31 for 24 hours. Hepatocyte and HSC cell area representative sections of the cell culture 
dish were photographed under 20x magnifications using a Nikon Eclipse TS100 inverted microscope with a 
Nikon DS-Vi1 head camera (Nikon, Düsseldorf, Germany). The measurement of cell area was performed using 
ImageJ (NIH, USA) and 5–10 cells were analysed per representative section.
Apoptosis assay. FACS analyses were performed to analyse apoptosis in rat hepatocytes by using the 
Annexin V Apoptosis Detectin Kit (KD Biosciences, Heidelberg, Germany) as previously described29.
DNA isolation and electrophoresis. DNA from rat hepatocyte samples incubated with agonist, antago-
nist or left untreated, was isolated using Apoptotic DNA ladder extraction Kit (BioVision, Mountain View, USA) 
according to the manufacturer’s guidelines. Samples were run in agarose gel, stained with ethidium bromide and 
visualized by transillumination with UV light, as described previously30.
Histology and immunohistochemical analyses. All analyses were performed on 5 μ m paraffin- 
embedded sections. Positive and negative controls were used to exclude non-specific staining. Immunohistochemistry 
(IHC) and immunofluorescent (IF) staining of KCa3.1 channels were performed in human samples. In brief, 
following paraffin removal and dehydration, sections were incubated with a primary antibody (anti-KCNN4 
#HPA05384, Sigma-Aldrich, St. Louis, MO, USA). For KCa3.1 IHC we used the PowerVision Poly-Horseradish 
peroxidase anti-Rabbit IgG (Dako, Glostrup, Denmark) as secondary antibody. For IF protocols we used an Alexa 
Fluor 488-labeled secondary antibody (Life Technologies, Darmstadt, Germany) for visualization. Finally, sec-
tions were counterstained with haematoxylin for IHC or diamidino-2-phenylindole dihydrochloride (DAPI) for 
IF. Human stained sections were reviewed with an Olympus BX51 microscope and pictures were captured with 
an Olympus DP26 camera in the cellSens program (Olympus, Hamburg, Germany).
For the detection of collagen fibres in mice, liver samples were stained with 0.1% Sirius red F3B in saturated 
picric acid (Chroma, Münster, Germany) using standard methods as described previously27. Further immuno-
fluorescent staining was performed with collagen1 on murine samples. In human tissue paraffin was removed 
and sections were dehydrated. Subsequently, sections were incubated with a primary antibody (anti-Collagen, 
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ab34710, Abcam, Cambridge, United Kingdom) and an Alexa Fluor 568-labeled secondary antibody (Life 
Technologies, Darmstadt, Germany) was used for visualization. Additionally, immunohistochemical analyses 
were performed for α SMA, which is a surrogate marker for hepatic stellate cell activation. The sections were incu-
bated with a mouse-anti-SMA antibody (Actin clone 1A4; Dako, Hamburg, Germany). Thereafter, a biotinylated 
goat-anti-mouse (Dako, Hamburg, Germany) secondary antibody was used. Finally, sections were counterstained 
with haematoxylin.
The histological stainings of the murine samples were digitalised using Panoramic MIDI (3DHistech, 
Budapest, Hungary). The amount of positive staining was evaluated by computational analysis (Histoquant; 
3DHistech, Budapest, Hungary). Large bile ducts and vessels were excluded. The analysis was performed follow-
ing the principles of computational analysis as described previously31,32.
Statistical analysis. Unless otherwise stated, data are given as means ± standard error of mean (SEM) and 
student’s t-test was used for group comparison when appropriate. Otherwise nonparametric tests were used. 
Wilcoxon test was used for paired comparison in the same group. Statistical analysis was performed using Prism 
5 (GraphPad, La Jolla, USA) software for Mac Os X. P values < 0.05 were considered statistical significant.
Results
KCa3.1 channels are upregulated in hepatocytes of fibrotic and cirrhotic human liver. Using 
immunohistochemical and immunofluorescence stainings, we evaluated the expression of KCa3.1 in non-fibrotic, 
fibrotic and cirrhotic human liver biopsies (Fig. 1). The corresponding general characteristics of the patients 
included are summarised in Table 1.
In non-fibrotic livers, regardless of the presence of inflammation, the KCa3.1 channels were only detectable 
in erythrocytes and vessel endothelium. KCa3.1 was predominantly expressed in hepatocytes of fibrotic livers 
and were seen to be overexpressed in hepatocytes of cirrhotic livers. In virtually all the hepatocytes KCa3.1 was 
distributed in the cirrhotic noduli and to a lesser degree in fibrotic septae, (Fig. 1).
KCa3.1 channels are upregulated in fibrotic livers in rodents. To confirm the findings in human 
tissue samples from diseased livers, KCa3.1 mRNA expression was analysed in mice following 8 and 12 weeks of 
CCl4 induced hepatic injury. Overall, KCa3.1 gene expression increased during liver fibrogenesis and increased 
with progression of hepatic injury, thereby confirming our data in patients (Fig. 2A). This effect was independent 
from the fibrosis model, since KCa3.1 expression was also significantly increased in TAA, CCl4 intoxicated and 
BDL rat livers (Fig. 2B).
In addition, in vitro, the expression of the KCa3.1 channel was significantly higher in hepatocytes compared to 
activated HSC (Fig. 2C), thereby validating our findings from immune staining of the human liver.
KCa3.1 inhibition induces hepatocyte apoptosis and alters hepatocyte volume. To dissect the 
effects of KCa3.1 in inhibition or activation of the cell cycle in hepatocytes, we measured the gene expression 
of the cell cycle mediators cyclin E1 (driving the release from quiescence) and cyclin A2 (controlling S-phase 
progression)33. Neither KCa3.1 inhibition with TRAM-34 nor activation with SKA-31 changed cyclin E1 and 
A2 expression significantly, and hence showed no direct effect on cell cycle progression (Fig. 2D). However, the 
KCa3.1 inhibitor TRAM-34, but not the activator SKA-31, induced apoptosis of hepatocytes, as shown by DNA 
ladder formation and FACS analyses of annexin V (Fig. 2E).
Pharmacologic manipulation of the KCa3.1 channel directly affected the cell volume of hepatocytes. Inhibition 
with TRAM-34 showed a clear trend towards increase in hepatocyte volume, whereas activation with SKA-31 sig-
nificantly reduced the cell volume (Fig. 2F).
KCa3.1 channel deficiency aggravates CCl4 induced liver fibrosis in mice. The KCa3.1−/− mice 
showed higher levels of hepatic hydroxyproline (Fig. 3A), and a higher deposition of collagen evaluated by Sirius 
red staining (Fig. 3B+ C) and collagen-1 staining (Fig. 3C). Similarly, the hepatic mRNA levels of TGFβ 1 and 
TNFα were increased in KCa3.1−/− mice after CCl4 intoxication compared to their respective wt littermates 
(Fig. 3D).
Hepatic protein expression of Proliferating Cell Nuclear Antigen (PCNA) was highly increased in KCa3.1 
deficient mice compared to wt mice after 12 weeks of CCl4 exposure (Fig. 3E+ F). Activation, but not expression 
of hepatic JNK, was significantly increased in fibrotic KCa3.1−/− mice compared to wt littermates (Fig. 3E+ F). 
Moreover, the hepatic protein expression of the c-Src activating phosphorylation (p-c-SrcThr418) was higher, 
whereas the protein expression of the c-Src deactivating phosphorylation (p-c-SrcThr530) was lower in knockout 
animals after 12 weeks of CCl4 compared to the respective wt mice (Fig. 3E+ F). These analyses suggest that prolif-
eration (PCNA) and volume control (c-Src activation) are dysregulated in knockout animals after hepatic injury.
KCa3.1 inhibition or deficiency stimulates HSC activity in vitro and in vivo. To better understand 
the reason for increased fibrosis in KCa3.1 deficient mice, activated hepatic stellate cells (HSC) were incubated 
with the KCa3.1 inhibitor TRAM-34 in vitro. TRAM-34 significantly suppressed collagen mRNA expression 
in activated HSC, however no significant effects could be observed on α -SMA and TGFβ mRNA expression 
(Fig. 4A).
Furthermore, TRAM-34 induced the cyclin E1 and A2 mRNA expression in activated HSC (Fig. 4B), which 
marks cell cycle progression. KCa3.1 channel stimulation, using SKA-31, however did not affect cell cycle pro-
gression (Fig. 4B). PCNA protein expression was increased in isolated HSC after KCa3.1 inhibition with TRAM-
34, while activation with SKA-31 did not impact proliferation (Fig. 4C).
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Similarly to findings in hepatocytes, TRAM-34 increased cell volume in HSC, but contrary to the hepatocytes, 
activation with SKA-31 showed no significant reduction in volume (Fig. 4D).
The in vitro results were confirmed by the in vivo observation of increased α -SMA positive staining, as a sign 
of increased HSC activation in fibrotic KCa3.1 deficient mice (Fig. 4E+ F).
KCa3.1 inhibition with Senicapoc worsens hepatic fibrosis. Since the genetic deficiency of the 
KCa3.1 channel might have different effects than the pharmacological inhibition in vivo, the KCa3.1 blocker 
Senicapoc was tested in CCl4 induced liver injury in wt mice by oral administration. Senicapoc treated mice ate 
less than the respective placebo (18,6 g/week vs. 22,9 g/week), but sufficient absorption of the drug was observed 
in all animals with average p-Senicapoc levels of 587.1 nM.
Senicapoc treated mice showed increased deposition of collagen, as evaluated by Sirius red (Fig. 5A+ B), and 
collagen1 mRNA levels (Fig. 5C). This was associated with higher HSC activation, as assessed by α -SMA staining 
(Fig. 5D+ E) and α -SMA gene transcription (Fig. 5F).
Figure 1. Distribution of KCa3.1 channel in non-fibrotic, fibrotic and cirrhotic human liver. KCa3.1 
channel expression evaluated by IHC top panel (I) (x10 magnification) and immunofluorescent stain (II) in 
bottom panel (x20 magnification). KCa3.1 channels are predominantly expressed in hepatocytes (a) of fibrotic 
and cirrhotic livers. Furthermore, KCa3.1 was detected in the vessel endothelium (b). To a minor degree KCa3.1 
positive staining is seen in the fibrotic septae of cirrhotic livers (c), probably in activated HSCs.
Parameters Non-fibrotic Fibrosis (F1–F2)
Advanced fibrosis/
cirrhosis (F3–F4)
Number 12 20 22
Gender (M/F) 4/8 6/14 15/7
Age, median (range) 42 (20–81) 56 (36–73) 59.5 (45–79)
Child pugh class, n (A/B/C) n.a. n.a 14/8/0
Fibrosis stage, median (range) 0 (0–0) 1 (1–2) 4 (3–4)
Inflammation stage, median (range) 0.2 (0–2) 2 (0–3) 1.5 (0–3)
ALT, median (range) U/L 94 (33–325) 135 (19–1210) 33 (6–1310)
Total bilirubin, median (range) μ mol/l 6.5 (4–23) 10 (5–539) 20 (7–90)
Alkaline phosphatase, median (range) U/l 122.5 (59–198) 141.5 (70–859) 129 (68–1301)
GGT, median (range) U/l 145.5 (46–801) 266 (54–1495) 194 (43–1401)
LDH, median (range) U/l 224 (113–282) 274 (194–663) 213 (98–420)
Albumin, median (range) g/l 41 (23–46) 41(21–46) 33.5 (22–42)
Creatinin, median (range) μ mol/l 65 (53–77) 71 (42–107) 70.5 (50–126)
Table 1. General characteristics of patients included for immunohistochemical analyses for hepatic KCa3.1 
localization and distribution.
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KCa3.1 inhibition does not alter portal pressure in vivo. Portal pressure measurements were per-
formed to evaluate the direct in vivo effect of TRAM-34 on portal hemodynamics in BDL and CCl4 cirrhotic rats. 
However, no significant changes in portal pressure, mean arterial pressure or heart rate were observed (Fig. 6).
Discussion
This study highlights the importance of the KCa3.1 channel in response to liver injury in humans and rodents. We 
demonstrate for the first time that the KCa3.1 channel is upregulated in hepatocytes with increasing liver fibrosis, 
while its absence or inhibition aggravates liver fibrosis.
The KCa3.1 channel is widely distributed in the organism, including the red and white blood cell linage34–36, 
epithelial cells of airway, colon and salivary glands, fibrocytes and vascular endothelial cells4–8, where as it’s 
hepatic expression is sparsely explored. A recent histopathological study based on stainings of only a few fibrotic 
liver samples reported that these channels are upregulated in hepatic fibrosis, and the channels might be located 
in activated HSC14. We confirmed that the KCa3.1 channel is expressed in HSCs. However, KCa3.1 was greatly 
upregulated in the damaged hepatocytes compared activated HSC of fibrotic livers. Similarly, we showed a sig-
nificantly higher expression of KCa3.1 mRNA in healthy hepatocytes compared to HSC in vitro, however there 
seems to a discrepancy between mRNA and transcription to protein, as expression of KCa3.1 evaluated by IHC, 
was absent in healthy human liver. The suggested anti-fibrotic effect of KCa3.1 inhibition in other fibroprolifer-
ative disorders has been linked to a suppressed effect on myofibroblast proliferation. In vitro, we were similarly 
able to show suppression of collagen1 mRNA in isolated HSC. However, although the fibrogenic pathways in all 
fibroproliferative diseases are highly similar, the liver differs from other organs by its unique highly regenerative 
potential – a capacity linked directly to the physiological roles of the hepatocytes. Upon injury, presence of apop-
totic hepatocytes stimulates the inflammatory response and hence fibrogenesis37. As KCa3.1 channels in the liver 
show a high hepatocyte expression compared to the expression seen in HSC, the mediated effect on hepatocytes 
may blunt any potential anti-fibrotic effect on HSC. The reason why KCa3.1 is found in activated HSC might be 
the profound changes that occur in these cells showing an increased proliferation, protein expression and migra-
tion. KCa3.1 might be one of the requirements of activated HSC to maintain their activated phenotype, since 
inhibiting it led to proliferation, but not to higher pro-fibrotic activity. The hepatocyte KCa3.1 expression and 
Figure 2. KCa3.1 expression in untreated and fibrotic rodents, cellular differences in distribution and 
effects. Similar to the differences between normal and fibrotic human livers, KCa3.1 channels are upregulated 
in fibrotic livers of mice (A) and rats (B) compared to untreated or sham animals. KCa3.1 is higher expressed in 
isolated hepatocytes compared to HSC (C). Incubation with the KCa3.1 inhibitor TRAM-34 or with the KCa3.1 
agonist did not affect significantly the cell cycle progression of hepatocytes (D). TRAM-34 directly stimulates 
hepatocyte apoptosis, as evaluated by increased DNA degradation and annexin V (E). KCa3.1 activation with 
SKA-31 showed no effects on DNA degradation and apoptosis (E). KCa3.1 inhibition with TRAM-34 showed a 
clear trend towards an increase in the hepatocyte cell volume, whereas activation with SKA-31 induced cellular 
shrinkage (F).
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effect on hepatocyte volume recovery seems important, and explains why the roles of KCa3.1 in the liver differ 
from effects seen in other parenchymal organs. Therefore, the deficiency or inhibition of KCa3.1 in vivo in models 
of liver injury is associated with hepatocellular damage and inflammation, which drives fibrogenesis, while the 
mild antifibrotic effects of KCa3.1-inhibition in activated HSC is not relevant in the in vivo setting.
Figure 3. Effect of genetic KCa3.1 depletion in CCl4 induced liver fibrosis in mice. KCa3.1−/− mice show 
increased fibrosis by the evaluation of hepatic hydroxyproline (A) and collagen, as evaluated by Sirius red and 
fluorescent stain for collagen1 (B,C) compared to wt littermates. These differences were especially pronounced 
in severe fibrosis, seen after 12 weeks of CCl4 exposure. Similarly, knockouts have higher expression of TGFβ 
mRNA, and increased inflammatory activity, as evaluated by the higher transcription of the TNFα gene (D). 
Representative Western blot analysis of the hepatic protein-expression of PCNA, JNK, pJNK, p-c-Src Thr418 
and 530 were analysed in fibrotic mice following 12 weeks CCl4 exposure. The hepatic expression of PCNA was 
higher in KCa3.1−/−. They similarly demonstrated increased pJNK and p-c-SrcThr418 expression, but lower 
Thr530 (E+F), suggesting a direct effect on c-Src and volume control (E,F).
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The expression of KCa3.1 increased with the severity of liver fibrosis in humans and in three different rodent 
models of liver fibrosis, suggesting that this is a common pathway irrespective of the species and type of liver 
injury. Although limited by the small number of animals in the rat experiments, these studies however support 
the findings from murine and human experiments. The attempt to demonstrate effects of KCa3.1 in a cholestatic 
mouse model (BDL) was not successful. A pilot study demonstrated a high mortality (> 80%) in operated KCa3.1 
knockout mice (data not shown), which was linked to a high number of post-operative complications, especially 
caused by suture rupture induced by the mice – the latter which may be linked to the hyperactive phenotype of 
KCa3.1 knockouts17.
Based on our findings, the exact role of KCa3.1 in hepatic injury and fibrogenesis is unknown. In several cell 
types (e.g. cancer cell lines, myofibroblasts) channel activation leads to calcium influx, and thereby stimulates 
cell cycle progression and cellular proliferation6,38,39. In other cell types (e.g. colon epithelial cells, erythrocytes) 
the channel regulates cell volume. Channel activation induces outflow of chloride and water, which leads to 
shrinkage40–43. In in vitro experiments with hepatoma cells, KCa3.1 regulated the cell volume3. This present study 
clearly supports these findings and shows that KCa3.1 is crucial for the homeostasis of hepatocytes upon injury. 
Supporting this hypothesis, we have shown that KCa3.1 activation was able to induce shrinkage of hepatocytes, as 
demonstrated by the reduction in cell volume. Approaches blocking this channel lead to cell cycle dysregulation 
and apoptosis in vitro, whereas the underlying mechanism might be a lack in the capacity to shrink after hepato-
cyte injury44. In vivo, activation of JNK and c-Src kinase was increased in KCa3.1 deficient fibrotic mice compared 
to the wild types assessed by their phosphorylation. It has been shown previously in vitro and in the isolated 
perfused rat liver, as reviewed in44–47, that hepatocyte swelling is directly linked to c-Src kinase, extracellular reg-
ulated kinase (Erk)-1/-2 and epidermal growth factor receptor (EGFR) activation in a α 5β 1-integrin-dependent 
manner resulting in hepatocyte proliferation. It is also a well-established concept that hepatocyte cell swelling 
is linked to proliferation, whereas hepatocyte shrinkage ends up in JNK- and CD95 death receptor-mediated 
apoptosis44–47. Interestingly, it has recently been reported, that KCa3.1 inhibition in human hepatoma HepG2 cell 
Figure 4. Effect of KCa3.1 deficiency and inhibition on activated HSC. In vivo, HSCs were incubated with 
TRAM-34 and SKA-31 and effect on profibrotic markers evaluated. Incubation with the KCa3.1 inhibitor 
TRAM-34 suppressed collagen-1 transcription. A similarly trend towards reduced expression was seen for 
TGF-β . α -SMA was reduced at levels similar to KCa3.1 activation with SKA-31, but was not significantly altered 
from control (A). Incubation with TRAM-34 was followed by an increase in cyclins E1 and A2 in HSCs (B), 
suggesting enhanced cell cycle progression. This was supported by increased protein expression of PCNA in 
isolated HSC (C). Similarly to findings in hepatocytes, TRAM-34 increased HSC volume, but contrary SKA-31 
was not able to reduce volume (D). CCl4 intoxication induces hepatic injury and leads to increased activation of 
HSCs in Kca3.1−/− mice, as evaluated by α -SMA immunohistochemistry (E+F).
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line cells, which most likely is accompanied by cell swelling, results in apoptosis48. Thus it might be an interesting 
speculation whether an overwhelming hepatocyte swelling in the context of liver regeneration after hepatic injury 
by either CCl4 or BDL in knockouts results in hepatocyte apoptosis and liver fibrosis. This is supported by our 
findings that in the KCa3.1 knockout mice a more pronounced c-Src and an increased hepatocyte injury became 
detectable. These findings account for a phenomenon associated with swelling since c-Src is usually de-activated 
in liver fibrosis as shown recently by our group49. The abundant KCa3.1 expression seen in human cirrhotic liver 
tissue may also be explained by a repair mechanism of the hepatocytes, which attempt to restore cell volume in the 
case of hepatocytes swelling caused by chronic liver injury. Our view is encouraged by recent studies in a model 
Figure 5. Effects of the KCa3.1 channel inhibitor Senicapoc in CCl4 induced hepatic injury in wt mice. 
Pharmacological KCa3.1 inhibition in CCl4 induced liver injury in mice led to increased liver fibrosis compared 
to wt littermates receiving placebo (A–C) and was similarly to the effects seen in KCa3.1−/− mice. Fibrosis was 
more severe as shown by Sirius red staining (A+B) and collagen-1 gene expression (C). Senicapoc treatment led 
to increased HSC activation as shown by immunohistochemiacal staining (D+E), as well as by gene expression 
levels (F) of surrogate marker α -SMA.
Figure 6. In vivo effects on hemodynamics of the KCa3.1 blocker TRAM-34 in bile duct ligated rats. In 
vivo, invasive measurement of portal pressure was performed in BDL and CCl4 cirrhotic rats before and after 
i.v. injection of TRAM-34 (100 nM). Following a 20 minutes observation period, no significant change in portal 
pressure (mmHg) could be observed (A). Measurements of mean arterial pressure (mmHg) and heart rate 
(beats/min) did not show any alterations compared to prior to TRAM-34 bolus (B+C).
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of alveolar epithelial repair in which a complementary role of the swelling activated β 1-integrin and KCa3.1 was 
described50. This again points to the importance of KCa3.1 in hepatocyte volume homeostasis and differentiated 
Src family kinase activation51 as it might protect hepatocytes from an overwhelming cell swelling in the context 
of hepatocyte proliferation.
Since the hepatocellular damage is more pronounced in fibrotic mice when KCa3.1 is deficient or blocked, the 
concomitant increased activation of HSC and fibrosis accumulation is expected. The mechanism by which the 
HSC get more activated after inhibition of KCa3.1 might be dual. On the one side the hepatocellular damage leads 
to more hepatic inflammation as shown by TNFα expression; on the other side the blocking the KCa3.1 channel 
as shown in vitro promotes proliferation. Furthermore, it has previously been reported that in quiescent HSC, in 
contrast to the hepatocytes, addition of death receptor ligands such as CD95L or TNFα are linked to proliferative 
signalling pathways. This might contribute to the increased activation of HSC after KCa3.1 inhibition as reported 
in this study, and is probably at least partly JNK-mediated52.
HSCs might not be as sensitive as hepatocytes in response to cell volume47. Interestingly we found that KCa3.1 
inhibition induced swelling in HSC, whereas activation was not able to induce shrinkage in these cells. Therefore, 
KCa3.1-inactivation might even lead to proliferation of these cells. In vivo, these harmful effects of KCa3.1 defi-
ciency or inhibition on liver fibrosis could not be ameliorated by a slight decrease in collagen transcription in 
vitro.
A previous study showed that acute administration of a pharmacological KCa3.1-blocker reduced hepatic 
resistance in in situ liver perfusion experiments14. This effect could not be confirmed in our set of in vivo experi-
ments. Therefore this is a strict in vitro effect without relevance for in vivo conditions when evaluating the effects 
on acute administration of the KCa3.1 blocker. Furthermore, the use of TRAM-34 in experimental settings may 
be challenged by the lack of selectivity of the blocker towards KCa3.153.
KCa3.1 blockers seem to be beneficial in renal and pulmonary fibrosis or other investigated disorders6,7,9,11–13. 
This study demonstrates, that in liver fibrosis, KCa3.1 expression and proper function is protective for hepatocel-
lular damage and fibrosis. Therefore, the activation of KCa3.1 might be advantageous in the context of liver injury.
Furthermore, the quantification of KCa3.1 expression could be a read-out for hepatocellular homeostasis 
during liver injury and under anti-fibrotic strategies.
In conclusion, our findings demonstrate that hepatic KCa3.1 activation is an important anti-fibrotic pathway 
and protects hepatocytes during liver injury and liver fibrosis.
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